Skip to content
Home » Emerging Pathogens & Novel Therapeutics

Emerging Pathogens & Novel Therapeutics

Emerging Pathogens & Novel Therapeutics

BREGOS: MRSA Bacteremia Retrospective Epidemiologic and Genomic Outcomes Study

PI:  Michael Z. David, MD, PhD

Study Dates:  2018-2023

Area of Focus: We will determine the frequency of likely transmission of MRSA leading to bacteremia in the hospital and to assess for bacterial genetic markers of poor outcomes in patients with MRSA bacteremia.

Specific Aims:

1. Compare the genomes of all infecting MRSA isolates to assess for genomic clustering of MRSA bacteremia isolates, suggesting local spread of one or more MRSA strains in the hospital or in the community.  

2. Determine clinical and genomic risk factors for 30-day mortality among MRSA patients.  

3. Assess which (if any) genomic factors (e.g., presence of mobile genetic elements, agr dysfunction, strain type) are associated with 30-day mortality or complications of bacteremia.
4.  Determine how often recurrent MRSA bacteremia is caused by a single clonal strain and how often a recurrence is caused by a new strain of MRSA.